Zacks Research Has Negative Outlook for ABEO FY2026 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Zacks Research lowered their FY2026 earnings estimates for Abeona Therapeutics in a research note issued on Monday, August 17th. Zacks Research analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of ($1.04) for the year, down from their prior forecast of ($0.94). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.90) per share.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The business had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million.

A number of other analysts also recently weighed in on the company. Oppenheimer restated an “outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday, August 14th. Weiss Ratings cut Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday, May 28th. Finally, Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.33.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $6.13 on Thursday. The company has a current ratio of 6.63, a quick ratio of 6.40 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $6.36 and a 200-day simple moving average of $5.60. The company has a market cap of $350.51 million, a price-to-earnings ratio of -5.62 and a beta of 1.35. Abeona Therapeutics has a 12-month low of $4.00 and a 12-month high of $7.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ABEO. AIGH Capital Management LLC grew its stake in Abeona Therapeutics by 55.0% in the 1st quarter. AIGH Capital Management LLC now owns 3,100,000 shares of the biopharmaceutical company’s stock valued at $13,888,000 after acquiring an additional 1,100,000 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in Abeona Therapeutics by 14.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after acquiring an additional 381,357 shares during the last quarter. Vanguard Group Inc. raised its position in Abeona Therapeutics by 3.8% during the third quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock worth $13,743,000 after acquiring an additional 95,878 shares during the last quarter. AWM Investment Company Inc. acquired a new position in Abeona Therapeutics during the second quarter worth about $9,184,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Abeona Therapeutics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 1,137,127 shares of the biopharmaceutical company’s stock valued at $5,994,000 after purchasing an additional 9,996 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Insiders Place Their Bets

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 67,971 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $6.96, for a total transaction of $473,078.16. Following the sale, the chief executive officer directly owned 1,306,108 shares in the company, valued at approximately $9,090,511.68. The trade was a 4.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Madhav Vasanthavada sold 12,606 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $6.96, for a total value of $87,737.76. Following the completion of the sale, the insider directly owned 290,623 shares in the company, valued at $2,022,736.08. This trade represents a 4.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 281,078 shares of company stock worth $1,709,923. 7.10% of the stock is owned by insiders.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.